The Lancet Oncology Publishes Phase I Data Demonstrating The Safety, Tolerability, And Preliminary Efficacy Of Cornerstone Pharmaceuticals, Inc.??? CPI-613 In Combination With Modified FOLFIRINOX In Patients With Metastatic Pancreatic Cancer

Press/Media: Press / Media

PeriodMay 9 2017

Media coverage

1

Media coverage

  • TitleThe Lancet Oncology Publishes Phase I Data Demonstrating The Safety, Tolerability, And Preliminary Efficacy Of Cornerstone Pharmaceuticals, Inc.??? CPI-613 In Combination With Modified FOLFIRINOX In Patients With Metastatic Pancreatic Cancer
    Media name/outletBioSpace
    CountryUnited States
    Date5/9/17
    PersonsAngela Alistar